Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
RESEARCH TOOLSreports
Sagimet Biosciences, Inc. Class A (SGMT) Stock Price & Analysis
189 Followers
SGMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.13 - $20.71
Previous Close$4.24
Volume325.61K
Average Volume (3M)760.88K
Market Cap
$128.87M
Enterprise Value$27.13M
Total Cash (Recent Filing)$101.84M
Total Debt (Recent Filing)$103.00K
Price to Earnings (P/E)-3.3
Beta4.82
Next Earnings
Mar 25, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume760,879
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.57
Enterprise Value/Gross Profit10.00T>
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$35.33Price Target Upside706.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Sagimet Biosciences, Inc. Class A News
Ownership Overview
71.35% Insiders
7.43% Mutual Funds
14.85% Other Institutional Investors
6.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $2.13 and its highest was $20.71 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Currently, no data Available
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Mar 25, 2024 which is 51 days ago.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Nov 13, 2023. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$1.028 by $0.678.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -$0.58.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 30,394,655 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.35 in its last earnings report, beating expectations of -$1.028. Following the earnings report the stock price went up 15.743%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Among the largest hedge funds holding Sagimet Biosciences, Inc. Class A’s share is Baker Bros Advisors LP. It holds Sagimet Biosciences, Inc. Class A’s shares valued at 8M.
---
Sagimet Biosciences, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.33 (706.62% Upside)
$35.33 (706.62% Upside)
Blogger Sentiment
Neutral
SGMT Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 369.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $63.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.4%
Last 30 Days ▲ 15.6%
Last 30 Days ▲ 15.6%
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
---
SGMT Stock 12 Month Forecast
Average Price Target
$35.33
▲(706.62% Upside)
Technical Analysis
Best Analysts Covering SGMT
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-23.36%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -23.36% per trade.
---